New Approvals for Kyprolis and Darzalex!
We are happy to annouce Darzalex (daratumumab), in combination with bortezomib and dexamethasone or with dexamethasone only, for relapsed/refractory multiple myeloma is now covered in New Brunswick (details).
According to the latest information from the government,Nova Scotia will also be reimbursing the cost of Darzalex. We hope to provide you with more details shortly.
As of April 26, 2019, in New-Brunswick , Kyprolis (carfilzomib) has been approved in combination with dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior treatments.